COMMUNIQUÉS West-GlobeNewswire

Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9

02/08/2018 - 14:00

SANTA MONICA, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]

Forty Seven Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference

02/08/2018 - 14:00

MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]

Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast

02/08/2018 - 14:00

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the second quarter ended June 30, 2018 and provide a [...]

Savara to Host Second Quarter 2018 Financial Results and Business Update Conference Call on Thursday, August 9, 2018

02/08/2018 - 14:00

AUSTIN, Texas, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced it will release its second quarter 2018 financial results on Thursday, August 9, 2018. Savara [...]

Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

02/08/2018 - 14:00

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, [...]

Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights

02/08/2018 - 14:00

-- Advancing Multiple Product Candidates into Clinical Trials with Dosing of First Patient in Phase 1 Trial of EDP1066 in Psoriasis and Atopic Dermatitis and FDA Acceptance of IND for Phase 2a Investigator-Sponsored [...]

OPKO Health to Announce Second Quarter 2018 Financial Results on August 7, 2018

02/08/2018 - 14:00

MIAMI, Aug. 02, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and six months ended June 30, 2018 after the close of the U.S. financial [...]

Obalon Announces Second Quarter 2018 Financial Results

02/08/2018 - 14:00

SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon [...]

Aptinyx Initiates Phase 1 Study of NYX-458

02/08/2018 - 14:00

Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative [...]

Photocure ASA: Presentation of the second quarter and first half year 2018 results

02/08/2018 - 08:11

Photocure will present its second quarter and first half year report on Wednesday 8 August 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be [...]

Shire plc : Rule 2.9 Announcement

02/08/2018 - 08:01

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 2 August 2018 [...]

Press Release: Terveystalo sells its Riga based subsidiary Ava Clinic

02/08/2018 - 08:01

On 31 July 2018, Terveystalo Group has entered into an agreement with Eugin Group, Europe's second largest group fully dedicated to human reproduction, whereby Terveystalo sells to Eugin Group the entire operation of [...]

Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular

02/08/2018 - 07:31

Press Release Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension ................................................. Study to randomize 420 patients in clinical sites across the U.S. [...]

Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire

02/08/2018 - 07:31

Communiqué de presse Nicox : Initiation d'une étude de phase 2 pour le NCX 470 dans le glaucome à angle ouvert et l'hypertension oculaire ................................................. Etude randomisée sur 420 [...]

VALNEVA Delivers Strong IXIARO® Sales Growth and reports Further Progress on Key R&D Programs in H1

02/08/2018 - 07:02

Valneva Delivers Strong IXIARO ® Sales Growth and r eports Further Progress on Key R&D Programs in H1 Double-digit sales growth driven by IXIARO ® Product sales of €53.5 million in H1 2018, representing 11.4% year [...]

VALNEVA publie une forte croissance des ventes d'IXIARO® et avance sur ses programmes R&D clés au S1

02/08/2018 - 07:02

Valneva publie une forte croissance des ventes d'IXIARO ® et avance sur ses programmes R&D clés au S1 Croissance à deux chiffres des ventes soutenue par IXIARO ® Ventes de produits de €53,5 millions au S1 2018, [...]

argenx reports second quarter business update and half-year 2018 financial results

02/08/2018 - 07:01

Management to host conference call today at 3 p.m. CEST / 9 a.m. EDT August 2, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a [...]

BioCryst Pharmaceuticals Prices Public Offering of Common Stock

02/08/2018 - 03:59

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock, [...]

Precision Therapeutics Receives Approval of Delisting Request from German Stock Exchange

02/08/2018 - 00:00

MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]